

33

**Mexican experience with direct-acting antivirals in the treatment of hepatitis C**



J.L. Pérez Hernández, C.A. Arce Salinas, R. Lehman Mendoza, A. Torre Delgadillo, G. Castro Narro, E. Cerda Reyes, M.V. Ramos Gómez, L. Juárez Chávez, M. Dehesa Violante, L. Muñoz Espinosa, L. Cisneros Garza, I. Aiza Haddad, J.A. Velarde Ruiz Velasco, R. Contreras Omaña, N. García Casarreal, J.A. Carmona Castañeda, M.F. Higuera de la Tijera

*Hospital General de México “Dr. Eduardo Liceaga” Ciudad de México, México*


**Background and aim:** Chronic hepatitis C infection, develops cirrhosis with all its complications, the arrival in our country of direct-acting antivirals (DAAs), gave the opportunity to have safer and more effective drugs.

**Material and methods:** Retrospective, cross-sectional study of patients who received AAD in hospitals in the Mexican Republic. 20 hospital centers. Variables analyzed: gender, age, genotype, degree of fibrosis, initial and final viral load of ADA treatment. SVR and side effects were documented. Descriptive statistics were performed.

**Results:** Were included 813 patients, 529 women and 284 men, age 58.88 ± 12.10 years were included. Genotype 1: 647 patients (1A: 316, 1B: 318, 1A / B: 11 and 1 A / C: 2), genotype 2: 145, genotype 3:19 and genotype 4: 2. By degree of fibrosis: F0: 93 F1: 88, F2: 86, F3: 95 and F4: 451. Patients with F4 (451), Child Pugh were classified as A: 363 and B: 88. From the Child Pugh group A 7 (1.9%) did not respond and from the group B 1 (1.1%). There were 561 naïve and 252 no naïve, the percentage that presented SVR was from 90 to 100%. The most frequent side effects: headache 16% and fatigue 22%, nausea (3%), muscle pain (1%), abdominal pain (1%), with ribavirin, anemia was documented in 22%.

**Conclusions:** Direct Action Antivirals is an effective and safe option in the Mexican population studied. Adverse events were not significant.

**Conflicts of interest:** The authors have no conflicts of interest to declare.



<https://doi.org/10.1016/j.aohep.2020.08.034>

34

**Characterization of patients with primary sclerosing cholangitis in a third level hospital**



V. López Ladrón de Guevara, C. Alonzo García, A. Vélez Carrión, F. Thomas Lora, B. Astudillo Romero, E. Márquez Guillén, C. Moctezuma Velázquez, N.C. Flores García, G. Castro Narro, A. Torre Delgadillo

*Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México*

**Background and aim:** Primary sclerosing cholangitis (CEP) is a syndrome of unknown cause, but it may be the result of an environmental insult that occurs in patients genetically susceptible to the disease, which would indicate an autoimmune component. Aim: To describe the clinical characteristics, treatment and complications of patients with Primary Sclerosing Cholangitis

**Material and methods:** Design: retrospective, cross-sectional study. It was held at INNSZ during 2009-2019. 40 patients were included with the diagnosis of Primary Sclerosing Cholangitis, Both genders, ages 18-69 years. Statistic analysis: Percentages, means, medians with standard deviation were used. The X<sup>2</sup> test was used. A value of p ≤ 0.05 was considered statistically significant with a 95% confidence interval. The analysis was carried out using the statistical package SPSS® v. 25

**Results:** The number of patients was 40, male predominance in 52.5%, with a median age of 53 years and body mass index of 22.9. 22.7% of the patients had arterial hypertension and Type 2 Diabetes Mellitus as comorbidity. Cholecystectomy was the surgical antecedent in 29.5%. The predominant symptom at the time of diagnosis was jaundice in 57.5%. Primary large duct sclerosing cholangitis was observed in 92.5%, cirrhosis in 83%. and association with ulcerative colitis in 67.6%. 77% of the patients received ursodeoxycholic acid. Recurrent cholangitis presented in 37.5%. Liver transplant 30%, mortality was 12.5%, identifying as cause of death: n = 2 due to complications from liver cirrhosis, n = 1 due to infection, n = 1 due to liver transplant complications and n = 1 due to cholangiocarcinoma.

**Conclusions:** 1. Primary Sclerosing Cholangitis was presented predominantly in men, with a median of aged 53 years and associated with UC, 77% of the patients received medical treatment with AUDC. 2. Complications: recurrent cholangitis and dominant stenosis. 3. Liver transplant in 30%. 4. Main cause of death was due to complications associated with liver cirrhosis.

**Conflicts of interest:** The authors have no conflicts of interest to declare.

<https://doi.org/10.1016/j.aohep.2020.08.035>

35

**Clinical, demographic, radiological and histological features of a series of liver adenomas in a reference hospital**



F.C. Thomas Lora, A. Torre Delgadillo, C. Moctezuma Velázquez

*Gastroenterology Department, National Institute of Medical Sciences and Nutrition Salvador Zubirán, México*

**Background and aim:** Liver adenomas are benign tumors of epithelial origin, infrequent, predominantly in women of child-bearing age, and associated with the use of oral contraceptives